期刊文献+

18F-FDGPET/CT显像评价肝泡型包虫病阿苯达唑脂质体治疗的疗效 被引量:8

18F-FDG PET/CT to evaluate the therapeutic effect of liposomal albendazole on hepatic alveolar echinococcosis
原文传递
导出
摘要 目的分析肝泡型包虫病(HAE)阿苯达唑脂质体治疗前后病灶边缘带放射性分布的变化,探讨18F-脱氧葡萄糖(FDG)PET/CT显像对疗效的评价价值。方法收集2011年7月至2015年7月问明确诊断为HAE患者37例[男21例,女16例;平均年龄(53+12)岁],患者均于服药前行18F-FDGPET/CT检查,测量病灶边缘带最大标准摄取值(SUVmax);按体质量服用阿苯达唑脂质剂10mg·d^-1·kg。6个月后再行全身18F-FDGPET/CT检查,测量SUVmax。采用两样本t检验分析数据。结果37例HAE患者中,阿苯达唑脂质体治疗前SUVmax为4.88±1.86,治疗后病灶边缘增殖浸润带放射性分布有不同程度减低;24例病灶体积缩小者SUVmax为3.63±1.38,较前差异有统计学意义(t=5.24,P〈0.001)。结论18F-FDGPET/CT显像对HAE阿苯达唑脂质体治疗前后肝内病灶活性的判断具有重要意义:HAE病灶边缘带放射性摄取程度可作为疗效评价的重要指标。 Objective To analyze the changes of radioactivity of the marginal zone of hepatic alveolar echinococeosis (HAE) before and after the treatment with albendazole liposomes, and to explore the value of 18F- fluorodeoxyglucose (FDG) PET/CT imaging in therapeutic response. Methods From July 2011 to July 2015, 37 patients (21 males, 16 females; average age (53±12) years) with HAE were selected and underwent 18F-FDG PET/CT imaging before routine medication with albendazole liposomes ( 10 mg · d^-1 · kg^-1 ), and the maximum standardized uptake value ( SUVmax ) of the margin of lesions was calculated. PET/CT imaging was per- formed again 6 months later to measure the SUVmax of the marginal lesions. Two-sample t test was used to an- alyze the data. Results In 37 patients with HAE, SUVmax before treatment was 4.88± 1.86, which was higher than that of 24 patients with reduced lesion size after treatment ( 3.63± 1.38 ; t = 5.24, P〈 0.001 ). Conclusion 18F-FDG PET/CT is useful for evaluating the radioactivity of marginal zone of HAE before and after the treatment with albendazole liposomes, and SUVmax of the marginal zone could be valuable for thera- oeutic resoonse evaluation.
出处 《中华核医学与分子影像杂志》 CAS 北大核心 2018年第2期101-103,共3页 Chinese Journal of Nuclear Medicine and Molecular Imaging
关键词 棘球蚴病 阿苯达唑 正电子发射断层显像术 体层摄影术 X线计算机 脱氧葡萄糖 Echinococcosis, hepatic Albendazole Positron-emission tomography Tomography,X-ray computed Deoxyglueose
  • 相关文献

参考文献2

二级参考文献14

  • 1蒋次鹏.泡球蚴病国外流行概况──记1995年国际泡球蚴病研讨会[J].地方病通报,1996,11(3):110-111. 被引量:3
  • 2唐群科,张瑛,李永寿,袁春萍,张冬天.肝泡球蚴病的治疗分析[J].寄生虫病与感染性疾病,2006,4(1):19-20. 被引量:4
  • 3李建辉,彭心宇,周宗瑶,吴向未,张示杰,牛建华,孙红.骨桥蛋白在肝细粒棘球蚴外囊壁中的表达[J].中国寄生虫学与寄生虫病杂志,2006,24(3):171-174. 被引量:9
  • 4任伟新,肖湘生,温浩.肝泡状棘球蚴病的影像学诊断及治疗进展[J].中国介入影像与治疗学,2007,4(4):314-317. 被引量:5
  • 5Wai PY, Kuo PC. Osteopontin: regulation in tumor metastasis [J]. Cancer Metastasis Rev, 2008, 27(1): 103-118.
  • 6Rangaswami H, Bulbule A, Kundu GC. Osteopontin: role in cell signaling and cancer progression[J]. Trends Cell Bilo, 2006, 16 (2) : 79-87.
  • 7Peng XY, Li JH, Wu X, et al. Detection of osteopontin in the pericyst of human hepatic Echinococcus granulosus[J]. Acta Trop, 2006, 100(3): 163-171.
  • 8Lund SA, Giachelli CM, Scatena M. The role of osteopontin in inflammatory processes[J]. J Cell Commun Signal, 2009, 3(3-4): 311-322.
  • 9O'Regan AW, Hayden JM, Body S, et ol. Abnormal pulmonary granuloma formation in osteopontin-deficient mice[J]. Am J Respir Crit Care Med, 2001, 164(12): 2243-2247.
  • 10E1-Tanani MK, Campbell FC, Kurisetty V, et ol. The regulation and role of osteopontin in malignant transformation and cancer[JJ. Cytokine Growth Factor Rev, 2006, 17(6): 463-474.

共引文献28

同被引文献53

引证文献8

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部